Literature DB >> 9688331

Increased levels of alpha-1-antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype.

F Licastro1, M Mallory, L A Hansen, E Masliah.   

Abstract

Levels of alpha-1-antichymotrypsin (ACT) were higher in brain homogenates of patients with Alzheimer's disease (AD) than controls. Brain tissues from the same patients and controls were immunostained with antibodies specific for microglia or astrocytes, the leukocyte common antigen (CD45) and glial fibrillary acidic protein (GFAP), respectively. Both activated CD45 and GFAP cells were increased in AD. Astroglia were divided into scattered (CD45sc) and clustered microglia (CD45cl) or scattered (GFAPsc) and clustered astrocytes (GFAPcl). Clustered cells were defined according their tendency to form focal aggregates. CD45cl and GFAPcl cells were present only in AD brain, while CD45sc and GFAPsc positive cells were present either in AD or control brains, with AD brains showing increased numbers of both cell types. A positive correlation between brain ACT levels and the number of GFAPsc positive cells was present in AD. AD patients with APOE 4 allele showed increased levels of ACT and increased CD45sc positive cells. Elevated ACT levels in the brain of AD patients could be interpreted as a metabolic response of astrocytes which might modulate the potentially deleterious activation of microglia cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9688331     DOI: 10.1016/s0165-5728(98)00096-4

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  17 in total

1.  CD45 opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activated protein kinase.

Authors:  J Tan; T Town; T Mori; Y Wu; M Saxe; F Crawford; M Mullan
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

2.  CD45 deficiency drives amyloid-β peptide oligomers and neuronal loss in Alzheimer's disease mice.

Authors:  Yuyan Zhu; Huayan Hou; Kavon Rezai-Zadeh; Brian Giunta; Amanda Ruscin; Carmelina Gemma; Jingji Jin; Natasa Dragicevic; Patrick Bradshaw; Suhail Rasool; Charles G Glabe; Jared Ehrhart; Paula Bickford; Takashi Mori; Demian Obregon; Terrence Town; Jun Tan
Journal:  J Neurosci       Date:  2011-01-26       Impact factor: 6.167

Review 3.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease.

Authors:  Greg M Cole; Sally A Frautschy
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-04       Impact factor: 4.388

4.  HIV-1 Tat-induced microglial activation and neuronal damage is inhibited via CD45 modulation: A potential new treatment target for HAND.

Authors:  Jingji Jin; Lucy Lam; Edin Sadic; Frank Fernandez; Jun Tan; Brian Giunta
Journal:  Am J Transl Res       Date:  2012-07-22       Impact factor: 4.060

5.  Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer's disease.

Authors:  Natalia Mast; Aicha Saadane; Ana Valencia-Olvera; James Constans; Erin Maxfield; Hiroyuki Arakawa; Young Li; Gary Landreth; Irina A Pikuleva
Journal:  Neuropharmacology       Date:  2017-06-24       Impact factor: 5.250

6.  A role for apoE in regulating the levels of alpha-1-antichymotrypsin in the aging mouse brain and in Alzheimer's disease.

Authors:  F Licastro; I L Campbell; C Kincaid; I Veinbergs; E Van Uden; E Rockenstein; M Mallory; J R Gilbert; E Masliah
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

7.  CD45 isoform expression in microglia and inflammatory cells in HIV-1 encephalitis.

Authors:  Melissa A Cosenza-Nashat; Mee-Ohk Kim; Meng-Liang Zhao; Hyeon-Sook Suh; Sunhee C Lee
Journal:  Brain Pathol       Date:  2006-10       Impact factor: 6.508

Review 8.  Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease.

Authors:  Micha M M Wilhelmus; Robert M W de Waal; Marcel M Verbeek
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

9.  CD45RB is a novel molecular therapeutic target to inhibit Abeta peptide-induced microglial MAPK activation.

Authors:  Yuyan Zhu; Huayan Hou; William V Nikolic; Jared Ehrhart; Elona Rrapo; Paula Bickford; Brian Giunta; Jun Tan
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

10.  Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation.

Authors:  Ethika Tyagi; Tina Fiorelli; Michelle Norden; Jaya Padmanabhan
Journal:  Int J Alzheimers Dis       Date:  2013-09-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.